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ABSTRACT
Whereas the role of the G-protein-coupled APJ receptor and its ligand, apelin, 
in angiogenesis has been well documented, the ability of the apelin/APJ system to 
induce lymphangiogenesis and lymphatic metastasis has been largely unexplored. 
To this end, we first show that APJ is expressed in lymphatic endothelial cells (LECs) 
and, moreover, that it responds to apelin by activating the apelinergic signaling 
cascade. We find that although apelin treatment does not influence the proliferation 
of LECs in vitro, it enhances their migration, protects them against UV irradiation-
induced apoptosis, increases their spheroid numbers in 3D culture, stimulates their 
in vitro capillary-like tube formation and, furthermore, promotes the invasive growth 
of lymphatic microvessels in vivo in the matrigel plug assay. We also demonstrate 
that apelin overexpression in malignant cells is associated with accelerated in vivo 
tumor growth and with increased intratumoral lymphangiogenesis and lymph node 
metastasis. These results indicate that apelin induces lymphangiogenesis and, 
accordingly, plays an important role in lymphatic tumor progression. Our study does 
not only reveal apelin as a novel lymphangiogenic factor but might also open the 
door for the development of novel anticancer therapies targeting lymphangiogenesis.
INTRODUCTION
The lymphatic system is essential for maintaining 
interstitial fluid homeostasis, immune cell trafficking and 
lipid transport. The lymphatic network also has an active 
role in different pathological conditions including tissue 
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inflammation, wound healing, renal and corneal graft 
rejection [1] but lymphatics are insufficient in patients 
with primary or secondary lymphoedema [2]. Although 
lymphatic spread frequently occurs in solid malignancies 
and is considered an indicator of local dissemination and 
poor prognosis, a long-established concept has assigned 
a passive role to lymphatics in tumor progression. 
However, recent animal studies using lymphangiogenic 
molecules have indicated that lymphatic vessels interact 
extensively with malignant cells and, moreover, that 
lymphangiogenesis is associated with, and can enhance, 
lymph node (LN) metastasis. The most widely studied 
molecular system that facilitates the expansion of 
the lymphatic network both under physiological and 
pathological conditions is the VEGF-C/ -D / VEGFR-3 
signaling pathway. Nevertheless, our knowledge of the 
molecular mechanisms that underlie lymphangiogenesis 
still lags far behind that of the vascular system [3]. 
Apelin has been recognized as the endogenous 
ligand of the human G protein–coupled receptor APJ 
[4], a member of the seven-transmembrane-receptor 
family. During embryonic development, APJ expression 
is largely restricted to the endothelial cells of the 
developing vascular system [5] and apelin is essential 
for vascular patterning of the embryo [6]. Nevertheless, 
apelin and its receptor are strongly expressed in the adult 
blood vasculature as well [7], and apelin was reported to 
stimulate blood endothelial cell growth in various in vitro 
[8, 9] and in vivo [6, 9] angiogenesis models. It has also 
been demonstrated that apelin can induce the maturation 
of tumor blood capillaries [10] and, moreover, that the 
apelin-APJ system is able to increase the vascularization 
and growth of different murine tumors [11]. Moreover, 
apelin was found to be upregulated in some human 
cancers [12-14], and both our group [15] and others [16, 
17] demonstrated a direct association of apelin expression 
with angiogenesis and/or clinical outcome in malignant 
disease. 
Apelin probably also has lymphangiogenic potential, 
however, evidence supporting this view has hitherto been 
obtained only in two very recent studies on the role of 
apelin in inflammation [18] and lymphatic development 
[19]. Therefore, and given the apelinergic system’s well 
established angiogenic potential under both physiological 
and pathological conditions, the present study was 
conducted to examine additional aspects of the apelin-APJ 
pathway in lymph vessel growth.
Here, we use in vitro and in vivo assays to dissect the 
role of apelin in lymphangiogenesis and lymphatic tumor 
spread. First, we investigate APJ expressions of LECs and 
analyze the downstream pathways upon activation of APJ 
signaling. Next, we assess LECs’ in vitro proliferation, 
migration, apoptosis and tube as well as spheroid 
formation following apelin treatment. We also quantify 
the in vivo effect of exogenous apelin on lymph vessel 
growth in the Matrigel plug system. Finally, we study 
whether transfection of tumor cells with apelin expression 
constructs results in an increase in lymphangiogenesis 
and LN metastasis in vivo. Our results provide the first 
direct evidence that apelin induces lymphangiogenesis and 
lymphatic metastasis. 
RESULTS 
APJ is expressed by human LECs and apelin 
activates its downstream signaling 
RT-PCR and immunocytochemical analysis of 
HUVECs (human umbilical vein endothelial cells) and 
LECs demonstrated the presence of APJ mRNA (Fig. 
1.A) and protein (Fig. 1. B-C) expressions, respectively. 
In order to demonstrate that APJ is functionally active 
in LECs, we investigated the activation of previously 
described downstream signaling molecules [8, 20]. 
We found that apelin led to a significantly increased 
phosphorylation of Erk1/2 and Akt after 5 and 15 
minutes treatment, respectively. Activation of S6 was 
not significant following apelin treatment (Fig. 1. D-E). 
Thus, APJ expressed in human LECs responds to apelin 
treatment by inducing the activation of the Erk and PI3K-
Akt pathways as we described in other cell types as well 
[8, 20]. 
Apelin does not increase the in vitro growth of 
LECs but promotes their migration and protects 
them against apoptosis
To investigate whether apelin alters LEC growth in 
vitro, the effect of apelin treatment on cell proliferation 
was studied by BrdU incorporation assay. Of note, 
exogenous apelin did not alter the in vitro proliferation 
rate of these cells, when compared with untreated cells 
after 96 h (Fig. 2. A-B).
Apelin has been shown to reduce apoptosis in 
various cell types, including retinal Müller cells [21], 
osteoblasts [22], neurons [23], vascular smooth muscle 
cells [24] and blood endothelial cells as well [6]. We used 
TUNEL analysis to investigate whether the apelin-APJ 
system can also inhibit programmed cell death in LECs. 
Using a standard serum starvation protocol, we found 
that 48 h serum deprivation did not result in significant 
apoptosis induction in LECs. However, administration of 1 
µM apelin significantly suppressed UV irradiation-induced 
apoptosis of LECs (P<0.05; Fig. 2. C-F). 
Next, we sought to determine the effect of apelin 
on human LEC migration. Using long-term time-lapse 
videomicroscopy in 2D cell cultures [25] (Fig. 3. A-B), 
we found that apelin at 100 nM significantly increased 
cell migration (P<0.05; Fig. 3. C-D), indicating a pro-
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Figure 1: Expression and activation of APJ receptor in LECs. (A) In LECs, APJ mRNA was detected at a comparable level to 
that in HUVECs. (B), Immunofluorescent staining of APJ (green) in HUVECs and LECs. Nuclei were labeled with PI (red). (D), Time 
course of phosphorylation of Erk1/2, Akt and S6 following 1 µM apelin-13 treatment of LECs. (E), Quantification of activation by the 
ratio of the phosphorylated and total protein levels shows robust and significant activation of Erk1/2 and Akt. No significant activation of 
S6 was found upon apelin treatment. Asterisks designate significant differences (P<0.05). Columns represent mean of three experiments; 
bars, SEM.
Figure 2: Proliferation and apoptosis of LECs following apelin treatment. (A), LECs were cultured in serum-free medium 
and treated with apelin. After 96 hours, cells were pulsed with BrdU, fixed and stained with an anti-BrdU antibody (green) and PI (red). 
(B), No significant change was found in the ratio of BrdU-labeled nuclei upon apelin treatments. (C-E), Apoptosis induction with UV in 
LECs. Apoptotic cells are labeled with TUNEL (green). DAPI nuclei staining is blue. White arrows indicate apoptotic nuclei. (F), Robust 
apoptosis was induced by UV irradiation. Apelin treatment significantly reduced the ratio of UV induced apoptotic cells. Asterisks designate 
significant differences (P<0.05). In (B) and (F), columns represent mean of three experiments; bars, SD. 
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migratory potential for apelin in addition to its anti-
apoptotic role in human LECs. Importantly, while APJ 
inhibition by F13A (an APJ antagonist) alone did not result 
in significant changes in cell migration, it reduced apelin-
induced LEC migration in a dose-dependent manner with 
complete inhibition when apelin and F13A was given at 
1:1 ratio (P<0.05; Fig. 3. C-D). Representative pictures of 
the LECs’ trajectories and their average migrated distance 
for 12 h intervals are also shown in Figure 3. A-B.
Apelin increases LEC spheroid numbers and 
stimulates capillary-like cord formation of LECs 
in vitro and, moreover, promotes the growth of 
lymph vessels in the Matrigel plug model in vivo
Three-dimensional spheroid endothelial cell models 
(introduced by Korff and Augustin in 1998 [26]) are useful 
tools for the analysis of the activity of pro- and anti-
angiogenic factors. Because apelin-APJ signaling has been 
reported to enhance proliferation and assembly of blood 
endothelial cells in spheroid cultures [27], we also tested 
the effects of apelin on the formation of multicellular 
spheroid structures by LECs (Fig. 4). Although apelin 
treatments at different doses (10 nM or 1 µM) did not 
result in significantly elevated mean spheroid diameters 
(Fig. 4. C), apelin (at 1 µM) significantly increased the 
number of LEC spheroids, when compared with untreated 
cells after 96 h (P<0.05; Fig. 4. D).
Endothelial tube formation assays are also regarded 
as in vitro models of more advanced stages of (lymph)
angiogenesis and are also often used to test the effects of 
different pro- and anti-(lymph)angiogenic molecules [28]. 
Thus, we examined the ability of apelin to promote LEC 
tube formation in a Matrigel tube formation assay and 
found that apelin (at 1 µM) was effective in promoting 
LEC differentiation into vascular structures in vitro 
(P<0.05 vs. control; Fig. 5. D). The extent of this effect 
was comparable to that of bFGF (basic fibroblast growth 
factor) at 20 ng/mL, which was used as a positive control 
(P<0.05 vs. control; Fig. 5. D). 
The Matrigel plug technique was used to study 
the effect of apelin on the invasive growth of lymphatic 
capillaries in mice. Corroborating the lymphangiogenic 
potential of apelin seen in the above described in vitro 
assays, LVDs were significantly higher in Matrigel plugs 
containing apelin (0.25 μg) or bFGF (0.25 μg) than in 
those with PBS only (P<0.05 in case of both apelin and 
bFGF); Fig. 5. E).
Figure 3: Effect of apelin on LEC migration. (A-B), Representative trajectories on the last phase contrast image of the path of 
LECs with (B) or without (A) apelin treatment. The color of the depicted trajectories refers to the elapsed time in the order from red–green–
blue. (C), Average migrated distances of human LECs after incubation with apelin-13 and/or F13A (an APJ antagonist). (D), 12h average 
migrated distance of LECs after incubation with 100nM apelin-13 significantly increased cell migration and it was reduced in a dose 
dependent manner by the addition of F13A. Asterisks designate significant differences (P<0.05). 
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Apelin overexpression confers a growth 
advantage to tumor grafts, induces intratumoral 
lymphangiogenesis and promotes lymphatic 
metastasis
We were also interested in investigating 
whether transfection of tumor cells with apelin 
expression constructs results in an increase in tumor 
lymphangiogenesis in vivo. Our studies to address this 
goal involved experiments with B16 mouse melanoma 
cells stably transfected with murine apelin (B16-apelin) 
Figure 6: In vivo growth of apelin expressing tumor 
cells. (A), Overexpression of apelin through genetic 
manipulation significantly stimulated the in vivo growth of 
murine B16 melanoma cells in C57BL/6 mice. Growth curves 
of control vector (B16 Mock)- and apelin-transfected (B16 
Apelin) cells.  and ■, means for 10 mice per group; bars, SD; *, 
P<0.05, versus control. (B-D), Apelin overexpression increases 
tumor-induced lymphangiogenesis in vivo. Frozen sections of 
18-day-old control (B) and apelin-overexpressing (D) tumors 
were stained for the LEC marker LYVE-1 (red). Magnification, 
x200 (B, D). (C), LVDs (mean lymph vessel counts per square 
millimeter) of 18-day-old apelin-overexpressing or of control 
B16 tumors. Columns, means for ten mice per group; bars, SD; *, 
P<0.05 vs. control. (E-F), Apelin-overexpressing B16 cells also 
developed significantly larger tumors (lower row) when injected 
into the footpads of mice (*, P<0.05). Ipsilateral inguinal LN 
regions were carefully examined under a stereomicroscope, 
photographed and removed (G) (arrowhead shows pigmented 
B16 cells in the LN). (H), Histological demonstration of LN 
metastasis of B16 melanoma. Asterisk shows the colony of 
metastatic B16 cells in a LN. (I), The percentages of metastatic 
ipsilateral inguinal LNs (as evaluated by stereomicroscopy and 
histology) were 89% and 30% in the B16-Apelin and B16-Mock 
groups, respectively (*, P<0.05).
Figure 5: Tube formation capacity of LECs upon 
apelin treatment in vitro and in vivo. (A-C), LECs (105) 
were plated on growth factor-reduced Matrigel-coated tissue 
culture plates in serum-free endothelial culture medium. 1 µM 
apelin-13 or 20 ng/ml bFGF was added to the medium. Capillary-
like structures within the Matrigel layer were photographed after 
18 hours. (D), Both apelin and bFGF significantly increased 
the average length of tubes (*, P<0.05 vs. control). Columns 
represent mean of three experiments; bars, SD; a.u., arbitrary 
unit (E), Matrigel containing PBS, apelin-13 (0.25 μg) or bFGF 
(0.25 μg) was injected subcutanously into mice. Both bFGF 
and apelin-13 significantly increased the density of LYVE-1 
stained tubular structures in the sections of one-week old plugs. 
Columns represent means of three experiments; bars, SD; *, 
P<0.05 vs. control. LVDs are mean lymph vessel counts per 
square millimeter. 
Figure 4: LEC spheroid formation in the presence of 
apelin. (A-B), LECs were plated in serum-free medium in 
non-adherent plates with apelin-13. After 96h incubation, all 
spheroids were photographed. (C-D), 1µM apelin-13 significantly 
increased the number of spheres without affecting their average 
diameter. Columns represent mean of three experiments; bars, 
SD; *, P<0.05 vs. control. Scale bar 100 µm 
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or with an empty plasmid vector (B16-mock) [29]. In the 
first set of animal experiments, we implanted tumor cells 
subcutaneously into the upper back of mice and assessed 
tumor volumes (Fig. 6. A) and intratumoral LVDs (Fig. 6. 
B-D). Importantly, morphometrical analysis using LYVE-
1 as a LEC marker (Fig. 6. B, D) revealed significantly 
higher LVDs present in the apelin-overexpressing 
tumors as compared with controls (P<0.05; Fig. 6. C). In 
addition, as expected [29], tumor growth was significantly 
accelerated in mice injected with B16-apelin cells 
compared with mice carrying B16-mock tumors (Fig. 6. 
A). 
Stimulation of intratumoral lymph capillary 
formation by apelin raised the possibility that this peptide 
might also enhance lymphatic metastasis. Thus, to further 
explore the role of apelin in lymphatic tumor progression, 
B16-apelin and B16-mock cells were also injected into 
the right hind footpads of mice in groups of ten animals 
per cell line. Two weeks after implantation, B16 tumors 
increased rapidly in size. Three weeks after injection, 
when the primary tumors were 5–9 mm in diameter (Fig. 
6. E-F), the animals were anaesthetized, and the ipsilateral 
inguinal LN regions were carefully examined under a 
stereomicroscope. In case of each animal, the LNs as 
well as the surrounding fat tissues were then removed and 
embedded into paraffin for serial sectioning. 8 of 9 (one 
mouse died at day 2 after tumor implantation in this group) 
animals (89%) in the B16-apelin group showed metastases 
by stereomicroscopic inspection (Fig. 6. G; metastatic LN 
from one representative mouse) and histology (Fig. 6. H). 
By contrast, only 3 of 10 animals (30%) in the B16-mock 
group had LN metastases (Fig. 6. I; P<0.05). 
DISCUSSION
Major progress has been made over the past two 
decades in understanding the molecular regulation 
of lymph vessel formation. Recent studies on 
lymphangiogenesis have been focused on two molecules 
of the VEGF (vascular endothelial growth factor) family, 
VEGF-C and -D, which are the ligands for VEGFR-3 
(VEGF receptor-3) [1, 3]. Although various therapeutic 
drugs have already been generated to target this molecular 
machinery, recent results suggest that lymphangiogenesis 
is a complex process which is regulated by additional 
signaling pathways [3, 30]. Further efforts are, therefore, 
needed for the better understanding of lymphatic biology 
to identify novel lymphangiogenic molecules and to 
develop more effective treatments for lymphangiogenesis-
related diseases, including cancer. In the present study, we 
provide evidence that apelin acts both in vitro and in vivo 
as a lymphangiogenic factor and, accordingly, that it has 
an important role in LN metastasis. 
First, we showed that LECs express APJ in vitro 
and that apelin acts through APJ to increase Erk and 
Akt phosphorylation. In a recent study investigating the 
functions of APJ signaling during lymphatic development 
in zebrafish embryogenesis, Kim et al. also found that 
the knockdown of APJ in LECs selectively reduced 
the basal levels of phospho-Akt, but without affecting 
the phosphorylation status of Erk [19]. These authors, 
however, investigated the impact of APJ signaling 
abrogation on the basal phospho-Erk levels of LECs in the 
presence of FBS (fetal bovine serum), while we analyzed 
the effect of apelin stimulation in serum-deprived LECs, 
which raises the possibility that the lack of decrease in 
Erk phosphorylation in their study was due to their 
different experimental approach. The results presented in 
the current paper are indeed consistent with our group’s 
earlier studies reporting that apelin induces the activation 
of both the PI3K-Akt and the Erk intracellular cascades 
in HUVECs (with endogenous APJ expression) and also 
in Chinese hamster ovary cells that have been stably 
transfected with APJ [8, 20]. Of note, both Akt [22, 24] 
and Erk [31-33] have also been shown to be downstream 
effectors of APJ signaling in various additional cell types 
including osteoblasts, vascular smooth muscle cells, 
embryonic kidney cells, neurons and cardiomyocytes 
(reviewed in ref. [34]). Additionally, VEGF-C/VEGFR3 
in LECs are also known to activate Akt and Erk signaling 
and, moreover, both molecular pathways have been 
implicated in both developmental and pathological 
lymphangiogenesis [35, 36]. Therefore, further studies are 
required to better understand the complex crosstalk among 
these intracellular cascades during lymphangiogenesis. 
APJ activation has been demonstrated to promote 
cell migration in a variety of cell types including retinal 
endothelial [9], Müller glial [37], oral squamous cell 
carcinoma [16] and mesendodermal [38] cells. In line with 
these studies, we also found a significant pro-migratory 
effect of apelin on LECs. Of note, our results gained by 
using long-term time-lapse videomicroscopy in 2D cell 
cultures are also in accordance with the findings of the 
recent study of Sawane et al. [18], in which they used 
a transwell migration assay to evaluate the migratory 
response of LECs to apelin. It is also important to mention 
that the pro-migratory effect of apelin was reduced in a 
dose-dependent manner by the addition of F13A (an apelin 
mutant that has been considered as an APJ antagonist [14, 
37, 39]). Our current findings, thus, suggest that F13A acts 
as a competitive antagonist on LECs when apelin-13 is 
present. 
EC spheroids are increasingly used for evaluating 
the pro- and anti-angiogenic potential of various factors 
and drugs [40]. Furthermore, it has been demonstrated that 
endothelial cells retain differentiated phenotypic properties 
in 3D spheroids while they tend to lose them in monolayer 
cultures [26]. Accordingly, we also evaluated the effects 
of apelin on the formation of LEC spheroids, and found 
that although it did not have an effect on spheroid sizes, 
it increased significantly their numbers. This observation, 
taken together with our further in vitro finding that apelin 
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stimulates the capillary-like tube formation of LECs, 
suggests an important role for apelin in the development 
of patent lymph capillaries via promoting a pro-adhesive 
state in the lymphatic endothelium. This assumption 
is also supported by recent studies reporting that apelin 
induces the endothelial expression of various intercellular 
adhesion molecules [10, 41, 42] and, accordingly, that it 
enhances the integrity of both blood and lymph capillaries 
[18, 43]. 
The apelinergic system is expressed in a diverse 
range of tissues with particular predominance in the 
blood vasculature [34, 44]. Accordingly, apelin has been 
shown to stimulate blood vascular EC growth in various 
in vitro [8, 9] and in vivo [6, 9] angiogenesis systems, 
including a mouse model of cancer [11]. Earlier studies 
have also provided evidence for apelin expression in 
human glioblastoma [12] and breast cancer [13]. We 
demonstrated recently a direct association of apelin 
expression with angiogenesis and clinical outcome in 
human non-small cell lung cancer [15] and, moreover, 
showed that autocrine apelin/APJ signaling participates 
in human colorectal cancer growth [14]. Another group 
demonstrated the prognostic significance of apelin 
expression in oral squamous cell carcinoma as well [16]. 
Most recently, circulating apelin levels were reported to 
be significantly increased in cancer patients (vs. healthy 
controls) and, moreover, to correlate with disease stage 
and prognosis [17]. Nevertheless, although the role of 
the apelinergic system during tumor progression and 
blood vessel formation has been an emerging focus of 
cancer and vascular research in recent years, whether 
and how apelin/APJ signaling contributes to tumor-
induced lymphangiogenesis and lymphatic metastasis 
remains unclear. Thus, given the biological and clinical 
significance of apelin in the progression of human cancers, 
we hypothesized that it might enhance tumor progression 
by exerting a stimulatory effect on lymph vessel formation 
as well. Investigating the lymphangiogenic activity 
of apelin in the in vivo Matrigel plug model, we found 
that apelin-containing Matrigel plugs had significantly 
higher lymph vessel counts than those with PBS alone. 
This effect of apelin was comparable to that of bFGF 
which is known as a potent lymphangiogenic factor 
[45]. More importantly, apelin overexpression of murine 
B16 melanoma cells significantly increased the burden 
and intratumoral lymphangiogenesis of tumors growing 
subcutaneously in mice. These data were corroborated 
by the observation of enhanced LN metastasis in mice 
carrying apelin-transfected primary tumors. Two recent 
studies from Sawane et al. reported that apelin decreases 
UVB-induced lymphatic capillary hyperpermeability 
[18] and stabilizes lymph capillary walls in a high-fat 
diet mouse model [43]. These data further support our 
results and, taken together with our findings, suggest 
that the apelinergic system regulates the adult lymphatic 
endothelium under both physiological and pathological 
conditions. The very recent paper of Kim et al. about the 
essential role of the apelin/APJ pathway during embryonic 
lymphatic development [19] puts this idea into an even 
broader perspective implying that the effects of apelin/APJ 
signaling on LECs are conserved from fishes to mammals 
and throughout embryonic development to adulthood. 
In conclusion, our study identifies apelin as a 
novel tumor lymphangiogenic factor that enhances LN 
metastasis. Accordingly, and based also on our group’s 
previous studies, the apelinergic system stimulates 
tumor progression through the following mechanisms: 
1./ promotion of blood capillary formation [11, 15], 2./ 
autocrine growth stimulation of malignant cells [14], and 
3./ enhancement of intratumoral lymphangiogenesis and 
LN metastasis. Development of potential future therapies 
targeting this complex pro-tumor function of the apelin/
APJ pathway is thus especially intriguing as it might offer 
benefits to patients with malignant diseases. 
MATERIALS AND METHODS
Cells
The B16 mouse melanoma cells stably transfected 
with murine apelin (B16-apelin) or with the empty 
plasmid vector (B16-mock) have been described in ref. 
[29]. HUVECs were purchased from Lonza (Walkersville, 
USA) and cultured in the manufacturer’s recommended 
medium (EGM®-2 BulletKit®, Lonza) at 370C in a 
humified incubator with 5% CO
2
. Telomerase reverse 
transcriptase (TERT)-transduced LECs (isolated from 
human foreskins, and generated and characterized as 
described previously [46, 47]), were grown in the same 
environment but in the EGM®-2-MV BulletKit® (Lonza) 
medium.
RNA isolation and real-time PCR
Total RNA was extracted from HUVECs and LECs 
using TRIzol® Reagent® (Invitrogen) and purified with 
DNAfree DNase kit (Applied Biosystems, California, 
USA) according to the manufacturer’s protocol. 2 μg of 
total RNA from each sample were reverse transcribed 
using High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems) according to the manufacturer’s 
protocol. Quantitative real-time PCR was performed 
using the cDNA as template with TaqMan Universal PCR 
Master mix (Applied Biosystems) and TaqMan premade 
gene expression assays (Applied Biosystems) to amplify 
APJ (Hs00270873_s1). All reactions were conducted as 
follows: 50ºC for 2 min and 40 cycles of 10s at 95ºC and 
1 min at 60ºC in an Applied Biosystems 7500 Real-time 
PCR System. All samples were assayed in triplicate and 
control water samples were included in each experiment. 
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The endogenous expression reference was the β-actin gene 
(Hs03023880_g1).
APJ receptor protein expression in HUVECs and 
human LECs 
For immuncytochemical stainings, HUVECs and 
human LECs (105 cells/well of a 24-well plate) were 
plated on fibronectin-coated coverslips. After 16 hours, 
cells were fixed in 4% PFA (10 min) and permeabilized 
with 0.1% Triton-X 100 solution (Sigma-Aldrich Co.) for 
1 minute. Then the cells were incubated with a mouse anti-
human APJ antibody (1:20; R&D Systems, Minneapolis, 
USA). Biotinylated anti-mouse IgG (Vector Laboratories, 
California, USA) served as the secondary antibody 
and was detected by fluorescein streptavidin (Jackson 
Immunoresearch, West Grove, USA). For the negative 
control, the primary antibody was omitted and only the 
secondary antibody was applied. Finally, counterstaining 
was performed using propidium-iodide (PI; Partec, 
Görlitz, Germany). All samples were viewed by confocal 
laser scanning microscopy using the LSM 700 system 
(Carl Zeiss AG, Jena, Germany).
In vitro Cell Proliferation Studies
Cell proliferation was examined using the 5-bromo-
2´-deoxyuridine (BrdU; Sigma-Aldrich Co.) incorporation 
assay. 4x103 human LECs per well were plated in a flat-
bottomed 96-well plate in serum-free medium, and 
were treated with apelin-13 (Phoenix Pharmaceuticals, 
Karlsruhe, Germany) at 0.5, 1, 10 and 100 nM 
concentrations. After 96 h, 2 mg/ml BrdU was added into 
the medium and the cells were incubated for an additional 
2 hours at 370C. BrdU-positive cells were labeled with 
anti-BrdU antibody (Becton-Dickinson, New Jersey, 
USA). Biotinylated anti-mouse IgG (Vector Laboratories) 
served as the secondary antibody and was detected by 
fluorescein streptavidin (Jackson Immunoresearch). 
Finally, all nuclei were stained with PI (Partec). Three 
random fields from 3 wells were photographed and the 
number of BrdU-positive and PI-positive cells in each 
field counted. The percentage of the BrdU-positive cells 
was calculated and averaged. 
LEC spheroid growth assay
To establish spheroid cultures from LECs, 
3x104 cells were seeded in triplicate in DMEM/Ham’s 
F-12 medium (PAA Laboratories, Pasching, Austria) 
supplemented with 20 ng/ml bFGF; (Eubio, Wien, 
Austria), 20 ng/ml epidermal growth factor (EGF; Sigma) 
and 2% B27 supplement (PAA Laboratories) in ultra low 
attachment 24-well plates (Corning Inc., New York, USA). 
Apelin-13 was added to the cells at 10 nM or 1 µM at the 
time of seeding. 96 hours after plating all spheroids in each 
well were photographed. In order to exclude small cell 
clumps from the analysis, only the spheres with a diameter 
over 100µm were counted and their diameter measured on 
the digital photographs using Image-J software.
Migration assay
The motility responses of human LECs to apelin 
were analysed by long-term time-lapse videomicroscopy 
in 2D cell cultures as described recently [25]. Briefly, 
LECs were plated in a 24-well plates (Corning Inc.) in 
a serum-free EBM-2 medium. The medium was changed 
to CO
2
-independent medium (Gibco, Paisley, UK) after 
the overnight cell attachment and apelin-13 or apelin-
13(F13A) (an APJ antagonist) [14, 37, 39] was added 
into the medium at 50 or 100 nM concentrations. Cells 
were kept in a custom designed incubator built around 
an inverted phase-contrast microscope (World Precision 
Instruments, Florida, USA) at 37°C and room ambient 
atmosphere. Images of 3 neighbouring microscopic fields 
were taken in every 5 min for 1 day before and 2 days after 
the treatment. For migration data, pictures were analysed 
individually with a cell-tracking program enabling manual 
marking of individual cells and recording their position 
parameters. The parameter migrated distance is calculated 
by averaging for each cell the displacement for the first 
24 hour interval after treatment, in two independent 
experiments and 4 microscopic fields.
Tube formation assay
Liquefied 10 mg/ml Matrigel Basement Membrane 
Matrix (0.289 ml/well; BD Biosciences, New Jersey, USA) 
was used to coat wells of a 24-well plate and then allowed 
to polymerize at 370C for a minimum of 30 min. 105 cells 
per well were seeded on basal membrane extract in serum-
free, EBM-2 medium (Lonza). The cells were treated with 
1 µM apelin-13 (Phoenix) or 20 ng/ml FGF (Eubio) and 
incubated 16-18 hours at 370C. Capillary-like structures 
within the Matrigel layer were then photographed and 
analyzed using Image J morphometry software.
Apoptosis assay
5x104 cells per well were cultured in a 24-well plate. 
After 24 hours, the cells were treated with 1 µM apelin-13. 
Apoptosis of cells was induced with an UV dose of 
200mW/cm2 for 10 seconds. After 48 hours incubation, 
cells were fixed in 4% PFA for 10 min. Apoptosis assay 
was carried out using the “In Situ Cell Death Detection” 
kit (Roche, Mannheim, Germany) and the protocol 
recommended by the manufacturer. Finally, cells were 
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coverslipped in Vectashield mounting medium containing 
DAPI (Vector Laboratories). Five random fields per slide 
were photographed and the percentage of TUNEL-positive 
cells among total cells was calculated and averaged.
Western Blot Analysis
LECs exposed to 1 µM apelin in serum-free medium 
(EBM-2, Lonza) for different time durations were lysed 
in RIPA-buffer (Fischer Scientific, Loughborough, UK), 
centrifuged, and protein was denatured before loading. 
Each sample was subjected to 12% sodium dodecyl sulfate 
(SDS)–polyacrylamide gel electrophoresis. The proteins 
were electro-transferred onto nitrocellulose membranes 
and immunodetected with antibodies against Akt-
pAkt, Erk1/2-pErk1/2, S6-pS6 (all from Cell Signaling 
Technologies, Massachusetts, USA) and β-actin (Sigma). 
Blots were then incubated with appropriate HRP-labeled 
secondary antibodies (Thermo Fisher Scientific, Rockford, 
IL, USA) and signals were detected by using the ECL 
system (GE Healthcare, Dassel, Germany). Activation of 
signaling was quantified as the ratio of phosphorylated and 
total protein densitometry measurements. 
Matrigel plug assay 
Groups of three C57BL/6 mice were injected 
subcutaneously with 0.25 ml Matrigel (BD Biosciences) 
containing PBS, 0.25 μg bFGF (Eubio), or 0.25 μg apelin 
(Phoenix Pharmaceuticals). One week after implantation, 
the plug was removed, and cryosections (5 μm) were 
prepared for immunohistochemistry. After labeling with 
rabbit anti-mouse LYVE-1 and rhodamine-conjugated goat 
anti-rabbit IgG (purchased from ReliaTech, Braunschweig, 
Germany and Jackson ImmunoResearch Inc., West Grove, 
PA, respectively), sections were examined using a Nikon 
Eclipse 80i microscope and digital images were captured 
using a SPOT digital camera (Diagnostic Instruments, 
Sterling Heights, MI). Quantitative analyses of the 
LYVE-1-positive lymphatic vessels in the Matrigels were 
performed using ImageJ software.
In vivo tumor studies
Growth of the apelin-transfected B16 mouse 
melanoma cells was compared with that of control vector 
expressing cells in allograft tumors formed in 9-week-old 
female BDF1 ((C57BL/6 x DBA/2)F1) mice. According 
to the institutional animal welfare guidelines, all mice 
were maintained on a daily 12-h light/12-h dark cycle 
and were housed under pathogen-free conditions in 
microisolator cages with laboratory chow and water ad 
libitum. B16-apelin and B16-mock cells were grown to 
80% confluence, harvested by trypsinization and washed 
twice. Tumor allografts were established by injecting 
mice subcutaneously with 1x106 B16-apelin or B16-mock 
cells under anesthesia with a combination of tiletamine 
hypochloride, zolazepam hypochloride, xylazin and 
butorphanol. Tumor size was measured every two days 
with a caliper and expressed in mm3 by the formula for 
the volume of a prolate ellipsoid (length x width2 π/6), 
as described previously [15, 48]. Tumors were removed 
from mice after 18 days of growth and were fresh-frozen 
in liquid nitrogen for further analysis. Lymph vessel 
densities (LVDs) were determined by labeling of lymph 
capillaries with rabbit anti-mouse LYVE-1 (ReliaTech) 
and rhodamine-conjugated goat anti-rabbit IgG (Jackson 
ImmunoResearch). Three sections per tumor were 
analyzed using a Nikon Eclipse 80i microscope. Digital 
images were captured and analyzed with a SPOT digital 
camera (Diagnostic Instruments) and the ImageJ software, 
respectively and as described previously [49, 50].
To study the LN metastatic potential of B16-
apelin primary tumors, in another set of in vivo tumor 
experiments, groups of ten mice were injected with B16-
apelin or B16-mock cells (1x106 cells per animal) in a 
total volume of 100 μl into the right hind footpad. Animals 
were euthanized and autopsied at 3 weeks postinoculation 
when the primary tumors reached 5-10 mm in diameter. 
Metastatic involvement of the ipsilateral inguinal 
sentinel LNs was evaluated with a stereomicroscope 
(Alpha, Woking, UK). The right-side inguinal LN of 
each animal were then collected, embedded in paraffin, 
serial sectioned, stained with haematoxylin and eosin and 
evaluated by a pathologist (BD).
Statistical analysis
Continuous variables were compared with Student’s 
t-test if the sample distribution was normal or with Mann-
Whitney U test if the sample distribution was asymmetric. 
Categorical data were compared using Fisher’s exact 
probability and χ2 tests. Differences were determined to 
be significant if p<0.05. All statistical analyses were done 
using GraphPad Prism 5.0 (GraphPad Software, Inc.; La 
Jolla, CA) software. 
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